Status:
RECRUITING
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Urothelial Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.
Eligibility Criteria
Inclusion
- 18-75 years old, male or female;
- Heart function is normal;
- Normal heart function;
- Estimated survival ≥12 weeks;
- Good follow-up compliance;
- presence of at least one measurable target lesion according to RECIST1.1 criteria;
- Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test;
- Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging;
- The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.
Exclusion
- Serious abnormality of liver, kidney and blood;
- Pregnant patients;
- Pregnant and lactation women;
- 3\) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.
Key Trial Info
Start Date :
May 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05321316
Start Date
May 31 2022
End Date
December 1 2024
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142